Richard C. Becker - JoVE Visualize

Showing results (221-230 of 329) with videos related to

Pageof 33

Sort By:

Circulation. Cardiovascular Genetics|March 10, 2015

NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes: Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO)Åsa Johansson, Niclas Eriksson, Richard C Becker, et al.

American Heart Journal|July 12, 2011

Troponin measurements during drug development--considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug AdministrationL Kristin Newby, Ignacio Rodriguez, John Finkle, et al.

Journal of Thrombosis and Thrombolysis|June 14, 2017

Platelet-related biomarkers and their response to inhibition with aspirin and p2y<sub>12</sub>-receptor antagonists in patients with acute coronary syndromeAngela Lowenstern, Robert F Storey, Megan Neely, et al.

Clinical Chemistry|December 10, 2016

Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary SyndromeDaniel Lindholm, Stefan K James, Maria Bertilsson, et al.

Journal of Thrombosis and Thrombolysis|June 25, 2005

Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committeeE Magnus Ohman, Christopher B Granger, Lawrence Rice, et al.

Hypertension (Dallas, Tex. : 1979)|October 26, 2018

Prediction of Ambulatory Hypertension Based on Clinic Blood Pressure Percentile in AdolescentsGilad Hamdani, Joseph T Flynn, Richard C Becker, et al.

American Heart Journal|February 15, 2011

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trialThomas J Povsic, Mauricio G Cohen, Roxana Mehran, et al.

Journal of the American College of Cardiology|October 2, 2012

Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgeryChristoph Varenhorst, Ulrica Alström, Benjamin M Scirica, et al.

Circulation|July 1, 2016

On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AFChristopher B Fordyce, Anne S Hellkamp, Yuliya Lokhnygina, et al.

American Heart Journal|August 10, 2016

Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF TrialSreekanth Vemulapalli, Anne S Hellkamp, W Schuyler Jones, et al.

Pageof 33

Showing results (221-230 of 329) with videos related to

Sort By:

Pageof 33

Circulation. Cardiovascular Genetics|March 10, 2015

NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes: Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO)Åsa Johansson, Niclas Eriksson, Richard C Becker, et al.

American Heart Journal|July 12, 2011

Troponin measurements during drug development--considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug AdministrationL Kristin Newby, Ignacio Rodriguez, John Finkle, et al.

Journal of Thrombosis and Thrombolysis|June 14, 2017

Platelet-related biomarkers and their response to inhibition with aspirin and p2y<sub>12</sub>-receptor antagonists in patients with acute coronary syndromeAngela Lowenstern, Robert F Storey, Megan Neely, et al.

Clinical Chemistry|December 10, 2016

Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary SyndromeDaniel Lindholm, Stefan K James, Maria Bertilsson, et al.

Journal of Thrombosis and Thrombolysis|June 25, 2005

Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committeeE Magnus Ohman, Christopher B Granger, Lawrence Rice, et al.

Hypertension (Dallas, Tex. : 1979)|October 26, 2018

Prediction of Ambulatory Hypertension Based on Clinic Blood Pressure Percentile in AdolescentsGilad Hamdani, Joseph T Flynn, Richard C Becker, et al.

American Heart Journal|February 15, 2011

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trialThomas J Povsic, Mauricio G Cohen, Roxana Mehran, et al.

Journal of the American College of Cardiology|October 2, 2012

Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgeryChristoph Varenhorst, Ulrica Alström, Benjamin M Scirica, et al.

Circulation|July 1, 2016

On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AFChristopher B Fordyce, Anne S Hellkamp, Yuliya Lokhnygina, et al.

American Heart Journal|August 10, 2016

Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF TrialSreekanth Vemulapalli, Anne S Hellkamp, W Schuyler Jones, et al.

Pageof 33